Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
34.28
+0.39 (+1.15%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
December 17, 2024
Via
ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
December 16, 2024
Via
ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
December 13, 2024
Via
ACCESSWIRE
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
August 06, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
April 30, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
October 31, 2023
From
Harmony Biosciences
Via
GlobeNewswire
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
August 17, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
NASDAQ: HRMY Investor Alert: Investigation over Potential Wrongdoing at Harmony Biosciences Holdings, Inc.
August 17, 2023
San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc.
Via
SBWire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID)
August 14, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
August 01, 2023
From
Harmony Biosciences
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Techtronic, Boxed, Coinbase, and Harmony and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
May 02, 2023
From
Harmony Biosciences
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
April 23, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
NASDAQ:HRMY Shareholder Alert: Investigation over Possible Securities Laws Violations by Harmony Biosciences Holdings, Inc.
April 14, 2023
San Diego, CA -- (SBWIRE) -- 04/14/2023 -- An investigation was announced for investors of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) shares over potential securities laws violations by Harmony...
Via
SBWire
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
April 12, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Nutanix and Harmony and Encourages Investors to Contact the Firm
April 02, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
March 30, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
March 30, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
HARMONY ALERT: Bragar Eagel & Squire, P.C. is Investigating Harmony Biosciences Holdings, Inc. on Behalf of Harmony Stockholders and Encourages Investors to Contact the Firm
March 29, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
March 29, 2023
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
March 28, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Lost Money in Harmony Biosciences Holdings Inc.?
March 28, 2023
From
Gibbs Law Group
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
March 28, 2023
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Harmony Biosciences Holdings, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – HRMY
March 28, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 21, 2023
From
Harmony Biosciences
Via
GlobeNewswire
2 Biotechs Making Waves With A Single Product in their Pipeline
January 11, 2023
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
Via
MarketBeat
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 01, 2022
From
Harmony Biosciences
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.